Patents by Inventor John P. MAYER

John P. MAYER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aqueously soluble and chemically stable glucagon peptides
    Patent number: 10683334
    Abstract: Modified glucagon peptides are disclosed having improved solubility and/or stability while retaining glucagon agonist activity. The glucagon peptides have been modified by the substitution of pyridyl-alanine for a native amino acid at one or more of positions 6, 10 or 13 and/or substitution with an amino acid in the D-conformation at position 20 or 21 compared to native glucagon.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 16, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, John P. Mayer, Piotr Mroz
  • Lipidated amide-based insulin prodrugs
    Patent number: 10385107
    Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: August 20, 2019
    Assignee: Indiana Univeresity Researc and Technology Corporation
    Inventors: Richard D. Dimarchi, Binbin Kou, Fa Zhang, John P. Mayer
  • AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES
    Publication number: 20190218268
    Abstract: Modified glucagon peptides are disclosed having improved solubility and/or stability while retaining glucagon agonist activity. The glucagon peptides have been modified by the substitution of pyridyl-alanine for a native amino acid at one or more of positions 6, 10 or 13 and/or substitution with an amino acid in the D-conformation at position 20 or 21 compared to native glucagon.
    Type: Application
    Filed: May 31, 2017
    Publication date: July 18, 2019
    Inventors: Richard D. DIMARCHI, John P. MAYER, Piotr MROZ
  • Incretin-insulin conjugates
    Patent number: 10232020
    Abstract: Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 19, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, John P. Mayer, David L. Smiley, Fa Liu
  • INCRETIN-INSULIN CONJUGATES
    Publication number: 20170281788
    Abstract: Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.
    Type: Application
    Filed: September 23, 2015
    Publication date: October 5, 2017
    Inventors: Richard D. DIMARCHI, John P. MAYER, David L. SMILEY, Fa LIU
  • LIPIDATED AMIDE-BASED INSULIN PRODRUGS
    Publication number: 20170283479
    Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Application
    Filed: September 23, 2015
    Publication date: October 5, 2017
    Inventors: Richard D. DIMARCHI, Binbin KOU, Fa ZHANG, John P. MAYER